Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The record now presents details for the GLORIOSA Phase 3 trial comparing mirvetuximab soravtansine plus bevacizumab with bevacizumab alone as maintenance therapy for certain platinum-sensitive ovarian, fallopian tube, or peritoneal cancers. It includes study design, eligibility requirements, participating locations, outcome measures, and information about sharing participant data.
    Difference
    100%
    Check dated 2026-11-10T18:25:56.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer’s site revision changes from v3.7.2 to v3.8.0 on the 403 error page; no study-record content changes.
    Difference
    0.2%
    Check dated 2026-11-03T18:38:54.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A banner announces an NIH terminology transition, and the site revision label changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T19:09:18.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1; the page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T19:37:08.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error instead of the expected content, indicating an access restriction. This is an error state rather than a content update to the study record.
    Difference
    0.5%
    Check dated 2026-09-29T19:31:25.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The GLORIOSA study page now displays a 403 Forbidden error instead of trial details, indicating an access/permissions issue. This prevents viewing the study information on ClinicalTrials.gov until access is resolved.
    Difference
    18%
    Check dated 2026-09-22T22:31:57.000Z thumbnail image

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.